Literature DB >> 32228738

Mortality Rate of Infection With COVID-19 in Korea From the Perspective of Underlying Disease.

Yun-Jung Kang1.   

Abstract

On December 31, 2019 the China National Health Commission (NHC) reported that an unknown cause of pneumonia had been detected in Wuhan in Hubei province. On February 12, the disease caused by the novel coronavirus (2019-nCoV) was given a formal name, COVID-19. On January 20, 2020, the first case of COVID-19 was confirmed in Korea. The age-specific death rate was the highest among patients over 70 years of age, with underlying diseases in their circulatory system, such as myocardial infarction, cerebral infraction, arrythmia, and hypertension. Patients with underlying disease who are 70 years of age or older should recognize that there is a high possibility of developing a serious disease in case of viral infection and follow strict precautions.

Entities:  

Keywords:  COVID-19; mortality rate; over 70; perspective; prevention; underlying diseases

Mesh:

Year:  2020        PMID: 32228738      PMCID: PMC7156566          DOI: 10.1017/dmp.2020.60

Source DB:  PubMed          Journal:  Disaster Med Public Health Prep        ISSN: 1935-7893            Impact factor:   1.385


On December 31, 2019, the China National Health Commission (NHC) reported that an unknown cause of pneumonia had been detected in Wuhan in Hubei province. The NHC later confirmed that the infection was a novel coronavirus-infected pneumonia (NCIP). On February 12, the disease caused by the novel coronavirus (2019-nCoV) was given a formal name, COVID-19. On January 20, 2020, the first case of COVID-19 was confirmed in Korea.[1] After the first COVID-19 case was confirmed on January 20, 2020, the Korea Centers for Disease Control and Prevention has focused on delaying the inflow of the virus into Korea and its spread in local communities, with considerable success. Also, the mortality rate of COVID-19 outside China was rather low, leading to the expectation that the disease’s impact on national health would be minor. However, things turned over rapidly after Case No. 31. The epidemic is spreading rapidly on a global level.[2] The Secretary General of World Health Organization, Tedros Adhanom Ghebreyesus, warned that the COVID-19 epidemic has reached its watershed and that every state should prepare for it.[3] Among the symptoms of COVID-19 are fever and minor respiratory symptoms, such as dry coughs, which overlap with other respiratory diseases; therefore, it is not easy to confirm a case based only on early symptoms. When the symptoms get worse and lead to serious respiratory symptoms, such as dyspnea, low oxygen saturation, and pneumonia, they can cause death.[4] The current situation in Korea regarding COVID-19 occurrences at 00:00, March 16, 2020, is as follows: the total number of confirmed cases are 8236, with 1137 released from quarantine among them. New confirmed cases are counted to be 74, while the total number of deaths is 75. Most of the dead had underlying diseases or were elderly (Table 1). The mortality rate is 1-2% but cannot be confirmed yet. Among the deaths, age-specific death rate was highest among patients over 70 years of age, with underlying diseases in their circulatory system, such as myocardial infraction, cerebral infraction, arrythmia, and hypertension. By the term “underlying diseases,” we refer to chronic diseases of the patient, such as hypertension, diabetes, asthma, renal failure, and tuberculosis.[5]
TABLE 1

Status and Characteristics of Domestic Deaths (00:00, March 16th)

Category Persons ( n ) Rate (%) Remarks
Deaths75Mortality rate (out of 8236 confirmed patients) 0.91%
Mortality rate by age30s (849 confirmed)10.12
40s (1147 confirmed)10.09
50s (1585 confirmed)60.38
60s (1024 confirmed)141.37
70s (531 confirmed)285.27
80s ≤ (270 confirmed)259.26
Underlying disease (can be duplicated)Circulatory system disease4762.7Myocardial infarction, cerebral infarction, arrhythmia, hypertension, etc.
Endocrine and metabolic diseases3546.7Diabetes, hypothyroidism, etc.
Mental illness1925.3Dementia, schizophrenia, etc.
Respiratory diseases1824.0Asthma, chronic obstructive pulmonary disease, pneumonia, etc.
Urinary and reproductive system diseases1114.7
Malignant neoplasm (cancer)1013.3
Nervous system diseases, etc.34.0
Digestive system diseases22.7
Blood and hematopoietic diseases11.3
High risk group65 y and older6181.3
underlying disease(o)7498.7

[source] Korea Centers for Disease Control and Prevention.

Status and Characteristics of Domestic Deaths (00:00, March 16th) [source] Korea Centers for Disease Control and Prevention. Korea had its first case of swine flu in May 2009, with the first death on August 15 the same year. After that, on October 26, the government announced children under 59 mo old, pregnant women, and mothers within 2 wk of delivery, citizens over 65 y old, patients with chronic lung diseases, chronic cardiovascular diseases (except for hypertension), diabetes, chronic renal diseases, chronic liver diseases, cancers, people with weakened immunity, and other patients with absorption risks as high risk group to the complications of the swine flu and recommended them treatment in time, according to its 6th version of the Guidelines for Preventing and Managing Swine Flu.[6] Currently, the Korea Centers for Disease Control and Prevention is planning to categorize patients according to their pulse, age, and underlying diseases they had upon being found infected; the Centers would transfer critical patients to negative pressure isolation rooms designated by the government for proper treatment. The Centers came up with this new plan in the situation where the number of confirmed cases and death increased rapidly, leading to the importance of judging and categorizing the seriousness of patients’ situation.[7] The Korean Diabetes Association argued that patients who are suffering underlying diseases with high risk of death should be given access to early diagnosis and treatment of COVID-19. It requested preferential opportunities of examination and hospitalization for people over 70 with diabetes when they had suspected symptoms. According to a recent research article on Chinese patients, which was published in The Journal of the American Medical Association, the overall death rate was 2.3% among 44,672 patients; however, the mortality rate leaped to 8.0% in people in their 70s and 14.8% in people in their 80s. Patients with diabetes also showed higher mortality rate of 7.3%.[8] Even when they are exposed to the virus on the same conditions, people with underlying diseases should be aware that they are more susceptible to infection than people without them, as they have weaker immunities; they must adhere to the prevention regulation strictly. Especially, citizens over 70 with underlying diseases should be classified as high-risk group and managed carefully. This research would be provided as a basic material for guidelines regarding disease prevention and management of high-risk group among confirmed cases for future infectious diseases.
  1 in total

1.  Understanding cardiopulmonary resuscitation decision making: perspectives of seriously ill hospitalized patients and family members.

Authors:  Daren K Heyland; Chris Frank; Dianne Groll; Deb Pichora; Peter Dodek; Graeme Rocker; Amiram Gafni
Journal:  Chest       Date:  2006-08       Impact factor: 9.410

  1 in total
  18 in total

1.  Mental Health of Communities during the COVID-19 Pandemic.

Authors:  Daniel Vigo; Scott Patten; Kathleen Pajer; Michael Krausz; Steven Taylor; Brian Rush; Giuseppe Raviola; Shekhar Saxena; Graham Thornicroft; Lakshmi N Yatham
Journal:  Can J Psychiatry       Date:  2020-05-11       Impact factor: 4.356

2.  A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis.

Authors:  Lvliang Lu; Wenyu Zhong; Ziwei Bian; Zhiming Li; Ke Zhang; Boxuan Liang; Yizhou Zhong; Manjiang Hu; Li Lin; Jun Liu; Xi Lin; Yuji Huang; Junying Jiang; Xingfen Yang; Xin Zhang; Zhenlie Huang
Journal:  J Infect       Date:  2020-07-04       Impact factor: 6.072

3.  Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature.

Authors:  Kalpana Thapa Bajgain; Sujan Badal; Bishnu B Bajgain; Maria J Santana
Journal:  Am J Infect Control       Date:  2020-07-10       Impact factor: 2.918

4.  Psychological impact of the COVID-19 outbreak on students in a French region severely affected by the disease: results of the PIMS-CoV 19 study.

Authors:  Stéphanie Bourion-Bédès; Cyril Tarquinio; Martine Batt; Pascale Tarquinio; Romain Lebreuilly; Christine Sorsana; Karine Legrand; Hélène Rousseau; Cédric Baumann
Journal:  Psychiatry Res       Date:  2020-11-05       Impact factor: 3.222

5.  The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up.

Authors:  P Muñoz; A Galar; P Catalán; M Valerio; T Aldamiz-Echevarría; C Cólliga; E Bouza
Journal:  Rev Esp Quimioter       Date:  2020-07-30       Impact factor: 1.553

6.  Variable effects of underlying diseases on the prognosis of patients with COVID-19.

Authors:  Yong Jun Choi; Ju-Young Park; Hye Sun Lee; Jin Suh; Jeung Yoon Song; Min-Kwang Byun; Jae Hwa Cho; Hyung Jung Kim; Hye Jung Park
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

Review 7.  Encountering COVID-19 as Endocrinologists.

Authors:  Eun Jung Rhee; Jung Hee Kim; Sun Joon Moon; Won Young Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-04-23

Review 8.  Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review.

Authors:  Giuseppe Lisco; Anna De Tullio; Vito Angelo Giagulli; Edoardo Guastamacchia; Giovanni De Pergola; Vincenzo Triggiani
Journal:  Endocrine       Date:  2020-08-10       Impact factor: 3.633

Review 9.  Epidemiology of COVID-19

Authors:  Cemal Bulut; Yasuyuki Kato
Journal:  Turk J Med Sci       Date:  2020-04-21       Impact factor: 0.973

10.  Mortality Rate of Patients With COVID-19 Based on Underlying Health Conditions.

Authors:  Won-Young Choi
Journal:  Disaster Med Public Health Prep       Date:  2021-05-03       Impact factor: 1.385

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.